Cargando…

Influence of ADT on B7-H3 expression during CRPC progression from hormone-naïve prostate cancer

Androgen deprivation therapy (ADT) is the standard care for advanced prostate cancer (PCa) patients. Unfortunately, although tumors respond well initially, they enter dormancy and eventually progress to fatal/incurable castration-resistant prostate cancer (CRPC). B7-H3 is a promising new target for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Ning, Xue, Hui, Lin, Yen-Yi, Dong, Xin, Classen, Adam, Wu, Rebecca, Jin, Yuxuan, Lin, Dong, Volik, Stanislav, Ong, Christopher, Gleave, Martin, Collins, Colin, Wang, Yuzhuo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581905/ https://www.ncbi.nlm.nih.gov/pubmed/37452083 http://dx.doi.org/10.1038/s41417-023-00644-9

Ejemplares similares

The role of mRNA splicing in prostate cancer
por: Lapuk, Anna V, et al.
Publicado: (2014)

Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model
por: Siewe, Nourridine, et al.
Publicado: (2022)

Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis
por: Botrel, Tobias Engel Ayer, et al.
Publicado: (2016)

The impact of hegemonic masculine ideals on self‐esteem in prostate cancer patients undergoing androgen deprivation therapy (ADT) compared to ADT‐naïve patients
por: Gentili, Caterina, et al.
Publicado: (2022)

Systematic Identification and Characterization of RNA Editing in Prostate Tumors
por: Mo, Fan, et al.
Publicado: (2014)

Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE
por: Santini, Daniele, et al.
Publicado: (2020)

Metabolic heterogeneity signature of primary treatment-naïve prostate cancer
por: Lin, Dong, et al.
Publicado: (2017)

Transport of ADT
por: Juha Sakkinen
Publicado: (2006)

Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review
por: Tresnanda, Raden Indra, et al.
Publicado: (2021)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021)

ADT and OBSBOX in 2016
por: Valuch, D, et al.
Publicado: (2017)

Framework of Intrinsic Immune Landscape of Dormant Prostate Cancer
por: Wong, Nelson K. Y., et al.
Publicado: (2022)

Aneustat (OMN54) has aerobic glycolysis‐inhibitory activity and also immunomodulatory activity as indicated by a first‐generation PDX prostate cancer model
por: Qu, Sifeng, et al.
Publicado: (2018)

Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
por: Chandrasekar, Thenappan, et al.
Publicado: (2015)

ADT fast losses MD
por: Priebe, A, et al.
Publicado: (2013)

The effect of strength training on muscle cellular stress in prostate cancer patients on ADT
por: Nilsen, T S, et al.
Publicado: (2016)

Amplification of MUC1 in prostate cancer metastasis and CRPC development
por: Wong, Nicholas, et al.
Publicado: (2016)

The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis
por: Iris Luk, Sze Ue, et al.
Publicado: (2014)

Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer
por: Feng, Ye, et al.
Publicado: (2019)

ADT and RF after LS1
por: Butterworth, A, et al.
Publicado: (2015)

Weniger Corona-Infektionen unter ADT?
por: Bublak, Robert
Publicado: (2020)

Bridging Arrays and ADTs in Recursive Proofs
por: Fedyukovich, Grigory, et al.
Publicado: (2021)

The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications
por: Ramnarine, Varune Rohan, et al.
Publicado: (2018)

Adjusting the duration of androgen deprivation therapy (ADT) based on nadir PSA for high risk localized prostate cancer patients treated with definitive external beam radiation therapy and ADT
por: Ayoub, Zeina, et al.
Publicado: (2022)

Timing of exercise for muscle strength and physical function in men initiating ADT for prostate cancer
por: Newton, Robert U., et al.
Publicado: (2020)

Severity of COVID-19 infection in prostate cancer patients and effect of ADT on disease presentation
por: García Fuentes, C., et al.
Publicado: (2021)

Systematically understanding the immunity leading to CRPC progression
por: Ji, Zhiwei, et al.
Publicado: (2019)

Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4
por: Li, Yinan, et al.
Publicado: (2017)

The LHC Transverse Damper (ADT) Performance Specification
por: Boussard, Daniel, et al.
Publicado: (2000)

The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer
por: Lawrenson, Ross, et al.
Publicado: (2014)

International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries
por: Liede, Alexander, et al.
Publicado: (2016)

Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer
por: Mahalingam, Devalingam, et al.
Publicado: (2023)

Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC)
por: Humphreys, Michael R, et al.
Publicado: (2013)

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Gupta, Eva, et al.
Publicado: (2014)

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
por: Henríquez, Iván, et al.
Publicado: (2021)

Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer
por: Wyatt, Alexander W, et al.
Publicado: (2014)

Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications
por: Dong, Xin, et al.
Publicado: (2022)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
por: Tan, Pui S, et al.
Publicado: (2014)

Correction: Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer
por: Mahalingam, Devalingam, et al.
Publicado: (2023)

Noise studies with new ADT pickups (MD4143)
por: Buffat, Xavier, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fbp8pgnsuufut84ff424vpjspm